Ionis Pharmaceuticals has given a deeper look at phase 3 data on inotersen in patients dealing with hereditary TTR amyloidosis. The anti-sense drug ignited a 20-point advancement versus a score of neuropathy impairment, implanting a marker for the approaching quarrel with Alnylam.
Carlsbad, California-based Ionis recorded top-line data from the trial back in May. Previously, Ionis reported the trial connected the transthyretin-targeting antisense drug to a statistically significant improvement in average neuropathy impairment score also known as mNIS+7 after 15 months but didn’t get too much into detail about the numbers.
“A 20-point benefit in mNIS+7 is unprecedented and could mean the difference between the ability to walk and being confined to a wheelchair for patients suffering from this debilitating and fatal disease,” Annabel Wang, M.D., an associate professor of neurology at the University of California and an investigator in the NEURO-TTR trial, stated.
Ionis also broadcasted the fact the change in mNIS+7 hit statistical significance after eight months. That number could play a vital role in the upcoming months and years as Ionis looks to paint inotersen as a better option for hATTR patients than Alnylam’s patisiran, which underwent its own phase 3 test last month.
Alnylam hasn’t presented any data from its trial as of yet. That is expected to change at an ATTR meeting in Paris in November that will give an early indication for which company is most likely going to succeed. Alnylam’s is set to present at 11:00am Ionis and Ionis will present right after at 11:20 am.